Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

被引：0
|
作者：
Fatemeh Karimi [1 ]
Mojtaba Aghaei [2 ]
Najmaldin Saki [1 ]
机构：
[1] Ahvaz Jundishapur University of Medical Sciences,
[2] Thalassemia & Hemoglobinopathy Research Center,undefined
[3] Health Research Institute,undefined
[4] Ahvaz Jundishapur University of Medical Sciences,undefined
来源：
Current Treatment Options in Oncology | 2025年 / 26卷 / 3期
关键词：
Polymorphisms; Treatment outcomes; Multiple Myeloma; Genetic markers; Personalized therapy; Biomarkers;
D O I：
10.1007/s11864-025-01295-8
中图分类号：
学科分类号：
摘要：
Multiple myeloma (MM) is a lymphoproliferative disorder that remains a fatal disease despite therapeutic advances.Treatment responses vary among MM patients due to biological factors, tumor characteristics, and genetic differences.Research indicates that genetic polymorphisms, particularly single nucleotide polymorphisms, may influence treatment efficacy and patient outcomes in MM.Ongoing research into these genetic factors may provide valuable insights into the underlying mechanisms of drug efficacy and resistance in this complex disease.
引用
下载
收藏
页码：197 / 212
页数：15
相关论文
共 50 条
  • [21] The proteasome and proteasome inhibitors in multiple myeloma
    Gandolfi, Sara
    Laubach, Jacob P.
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Richardson, Paul G.
    CANCER AND METASTASIS REVIEWS, 2017, 36 (04) : 561 - 584
  • [22] Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma
    Raje, Noopur
    Hideshima, Teru
    Anderson, Kenneth C.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (09) : 1239 - 1247
  • [23] Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma
    Chang, Xiubao
    Zhu, Yuanxiao
    Shi, Changxin
    Stewart, A. Keith
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2014, 46 (03) : 240 - 253
  • [24] Immunomodulatory drugs in multiple myeloma
    Andhavarapu, Swati
    Roy, Vivek
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 69 - 82
  • [25] Immunomodulatory drugs in multiple myeloma
    Zangari, M
    Elice, F
    Tricot, G
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) : 1411 - 1418
  • [26] Use of proteasome inhibitors in the treatment of patients with multiple myeloma
    Rukavitsyn, O. A.
    TERAPEVTICHESKII ARKHIV, 2006, 78 (10): : 40 - 44
  • [27] Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
    Merin, Noah M.
    Kelly, Kevin R.
    PHARMACEUTICALS, 2015, 8 (01) : 1 - 20
  • [28] Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma
    Baljevic, Muhamed
    Orlowski, Robert Z.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (06) : 459 - 473
  • [29] Proteasome inhibitors for multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 785 - 792
  • [30] Proteasome Inhibitors in Multiple Myeloma
    Anderson, Kenneth C.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S20 - S26
12345